Table 1.

Clinicopathologic features of 26 cases of prostatic small cell carcinomas from Chinese literature.

No.	Age	PSA level (ng/mL)	Diagnostic procedure	Treatment	Pathologic type	Time of follow-up (months)	Survival status
1	76	0. 81	TURP	Non	pure	6	death
2	32	0.45	radical	Chemotherapy	pure	10	death
3	61	2.4	biopsy	Non	pure	1	lost
4	43	8.8	biopsy	Chemotherapy	pure	1	Survival with tumor
5	64	<4	TURP	Endocrine therapy	mixed	5	death
6	57	25.78	biopsy	Non	mixed	7	death
7	76	<4	TURP	Endocrine therapy	mixed	8	death
8	56	<4	radical	Endocrine therapy	pure	17	Survival with tumor
9	32	<4	biopsy	Chemotherapy	pure	3	lost
10	65	<4	biopsy	Chemo+Radiotherapy	pure	11	death
11	21	0.69	biopsy	Endocrine therapy	pure	3	death
12	82	2.26	TURP	Endocrine therapy	pure	3	death
13	61	0.32	radical	Chemotherapy	pure	3	Survival with tumor
14	55	<4	radical	Endocrine therapy	pure	3	death
15	34	<4	biopsy	Chemotherapy	pure	13	death
16	62	<4	radical	Non	pure	5	Survival with tumor
17	65	1.92	biopsy	Chemo+Endocrine+Radiotherapy	pure	11	death
18	55	<4	radical	Endocrine therapy	pure	3	death
19	34	<4	biopsy	Chemotherapy	pure	12	Survival with tumor
20	50	0.31	radical	Non	pure	1	death
21	82	2.61	TURP	Chemo+Endocrine therapy	pure	17	Survival with tumor
22	81	39.26	biopsy	Non	pure	5	death
23	77	25.02	biopsy	Chemo+Endocrine therapy	pure	2	Survival with tumor
24	79	18.12	biopsy	Endocrine therapy	mixed	2	death
25	76	<4	biopsy	Non	pure	8	death
26	65	20.67	biopsy	Endocrine therapy	mixed	4	Survival with tumor